THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Wednesday, September 22, 2021
Blaustein is a veteran biopharmaceutical executive with over 20 years of experience building and leading companies and critical business functions, including operations, program management, business development, and manufacturing.
FREMONT, CA: Finch Therapeutics Group, a clinical-stage microbiome therapeutics firm leveraging its Human-First Discovery platform to produce a novel class of orally administered biological drugs, recently appointed Marc Blaustein as the Chief Operating Officer. Blaustein is a veteran biopharmaceutical executive with over 20 years of experience building and leading companies and critical business functions, including operations, program management, business development, and manufacturing.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
“I am delighted to welcome Marc to the Finch team at a time when we are positioned to make significant advancements across our microbiome therapeutics platform,” said Mark Smith, Ph.D., Chief Executive Officer of Finch Therapeutics. “Marc has demonstrated immediate impact within the companies he joins and we believe his broad skillset and successful track record in drug development and commercialization will be invaluable to our organization. I look forward to leveraging Marcs experience and operational expertise as Finch enters its next phase of growth, with our lead candidate in late-stage clinical development and a growing pipeline of programs headed towards the clinic with an expected data-rich period ahead.”
“The field of microbiome therapeutics is an incredibly exciting emerging target for innovation and Finch’s platform offers a novel modality to potentially address a wide range of serious unmet medical needs. I am thrilled to join Finch at such a pivotal time and hope to draw from my experience to continue building upon the momentum generated by Finch’s promising clinical data and translational research,” said Blaustein.
Blaustein recently consulted as the Head of Business Development for Guide Therapeutics, which was brought by Beam Therapeutics in 2021. Before Guide Therapeutics, Blaustein was the CEO of NED Biosystems and co-founder and CEO of Akashi Therapeutics. Before founding Akashi, he served in several leadership positions across several biotechnology companies, including Senior Vice President of Manufacturing, Process, and Commercial Operations at Dyax(now Takeda), where he led the expansion of Kalbitor. Before Dyax, Blaustein held business development and management positions at Alkermes, where he introduced and led the development program for Vivitrol. Before Alkermes, Blaustein worked in business development at Genetics Institute (now Pfizer). He began his career in management consulting, first at Mercer Management Consulting and then as a founding partner of Northbridge Consulting. Blaustein got his master’s degree in Public Policy from Harvard University and recieved a bachelor’s degree in Biology from the University of Pennsylvania. Additionally, he is also a Chartered Financial Analyst (CFA) charter holder.
More in News